An interventional study of Single injection posterior tibial nerve block and Posterior tibial nerve catheter in Hallux Valgus, sponsored by Northwestern University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-05-27.
Sponsored by Northwestern University · Not applicable, Interventional, and Treatment
Foot surgery often causes severe and prolonged pain postoperatively. Prior methods of postoperative pain control included oral narcotics, single injection regional techniques and more recently continuous nerve catheters. Recent studies have demonstrated a benefit with continuous popliteal catheters when compared to single injection techniques in regards to postoperative pain control and patient satisfaction for foot surgeries.
Nerve blocks in the popliteal fossa involve both the common peroneal nerve and the tibial nerve. The innervation to the plantar surface of the forefoot involves the tibial nerve and does not involve the peroneal nerve. The purpose of this study is to compare the continuous posterior tibial nerve catheter with a single injection posterior tibial nerve block when used as part of a surgical ankle block for forefoot surgery.
144 studies on the registry are indexed under Hallux Valgus; 31 are open to participants now.
Browse Hallux Valgus studies →Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.
Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
Drug: Posterior tibial nerve catheter
Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
Drug: Single injection posterior tibial nerve block
5 ml of 0.5% ropivacaine
Also known as: Naropin
5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
Also known as: Naropin
Quality of recovery
Quality of recovery
Time frame: Up to five days
Pain control (pain score)
pain control (pain score) between groups
Time frame: Up to 1 week
Opioid consumption
Opioid consumption
Time frame: Up to 1 week
patient satisfaction
patient satisfaction with pain control
Time frame: Up to 1 week
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northwestern University